176 related articles for article (PubMed ID: 37114129)
1. Paradoxical activation of chronic lymphocytic leukemia cells by ruxolitinib
Spaner DE; Luo TY; Wang G; Schreiber G; Harari D; Shi Y
Front Oncol; 2023; 13():1043694. PubMed ID: 37114129
[TBL] [Abstract][Full Text] [Related]
2. Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial.
Spaner DE; Luo Y; Wang G; Gallagher J; Tsui H; Shi Y
Cancer Med; 2021 Dec; 10(24):8789-8798. PubMed ID: 34791813
[TBL] [Abstract][Full Text] [Related]
3. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM
Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085
[TBL] [Abstract][Full Text] [Related]
4. Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.
Spaner DE; McCaw L; Wang G; Tsui H; Shi Y
Cancer Med; 2019 Apr; 8(4):1540-1550. PubMed ID: 30843659
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.
Shi Y; Wang G; Muhowski EM; McCaw L; Wang C; Bjarnason G; Woyach JA; Spaner DE
Leukemia; 2019 Jul; 33(7):1650-1662. PubMed ID: 30696950
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis.
Delvecchio VS; Sana I; Mantione ME; Vilia MG; Ranghetti P; Rovida A; Angelillo P; Scarfò L; Ghia P; Muzio M
Br J Haematol; 2020 May; 189(3):475-488. PubMed ID: 32057093
[TBL] [Abstract][Full Text] [Related]
7. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
8. Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
Xia M; Luo TY; Shi Y; Wang G; Tsui H; Harari D; Spaner DE
J Immunol; 2020 Nov; 205(10):2629-2639. PubMed ID: 33067379
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells.
Mestre-Durán C; Martín-Cortázar C; García-Solís B; Pernas A; Pertíñez L; Galán V; Sisinni L; Clares-Villa L; Navarro-Zapata A; Al-Akioui K; Escudero A; Ferreras C; Pérez-Martínez A
Front Immunol; 2022; 13():1045316. PubMed ID: 36685552
[TBL] [Abstract][Full Text] [Related]
10. Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine.
Wolska A; Cebula-Obrzut B; Smolewski P; Robak T
Leuk Lymphoma; 2013 Jun; 54(6):1268-78. PubMed ID: 23078646
[TBL] [Abstract][Full Text] [Related]
11. Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells.
Oppermann S; Lam AJ; Tung S; Shi Y; McCaw L; Wang G; Ylanko J; Leber B; Andrews D; Spaner DE
Oncotarget; 2016 Nov; 7(45):72608-72621. PubMed ID: 27579615
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.
Tan Y; Watkins AA; Freeman BB; Meyers JA; Rifkin IR; Lerner A
J Immunol; 2015 Jan; 194(1):101-12. PubMed ID: 25416804
[TBL] [Abstract][Full Text] [Related]
13. Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells.
Rozovski U; Harris DM; Li P; Liu Z; Jain P; Veletic I; Ferrajoli A; Burger J; Thompson P; Jain N; Wierda W; Keating MJ; Estrov Z
Int J Cancer; 2017 Nov; 141(10):2076-2081. PubMed ID: 28722170
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells.
de Totero D; Meazza R; Zupo S; Cutrona G; Matis S; Colombo M; Balleari E; Pierri I; Fabbi M; Capaia M; Azzarone B; Gobbi M; Ferrarini M; Ferrini S
Blood; 2006 May; 107(9):3708-15. PubMed ID: 16391014
[TBL] [Abstract][Full Text] [Related]
15. Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.
Hofland T; de Weerdt I; Ter Burg H; de Boer R; Tannheimer S; Tonino SH; Kater AP; Eldering E
J Immunol; 2019 Oct; 203(8):2100-2109. PubMed ID: 31511358
[TBL] [Abstract][Full Text] [Related]
16. The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways.
de Totero D; Meazza R; Capaia M; Fabbi M; Azzarone B; Balleari E; Gobbi M; Cutrona G; Ferrarini M; Ferrini S
Blood; 2008 Jan; 111(2):517-24. PubMed ID: 17938255
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells.
Rozovski U; Wu JY; Harris DM; Liu Z; Li P; Hazan-Halevy I; Ferrajoli A; Burger JA; O'Brien S; Jain N; Verstovsek S; Wierda WG; Keating MJ; Estrov Z
Blood; 2014 Jun; 123(24):3797-802. PubMed ID: 24778152
[TBL] [Abstract][Full Text] [Related]
18. Low Density Lipoproteins Amplify Cytokine-signaling in Chronic Lymphocytic Leukemia Cells.
McCaw L; Shi Y; Wang G; Li YJ; Spaner DE
EBioMedicine; 2017 Feb; 15():24-35. PubMed ID: 27932296
[TBL] [Abstract][Full Text] [Related]
19. Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A.
Li Y; Shi Y; McCaw L; Li YJ; Zhu F; Gorczynski R; Duncan GS; Yang B; Ben-David Y; Spaner DE
Blood; 2015 Aug; 126(6):766-78. PubMed ID: 26041742
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-21 enhances Toll-like receptor 2/4-mediated cytokine production via phosphorylation in the STAT3, Akt and p38 MAPK signalling pathways in human monocytic THP-1 cells.
Jian L; Sun L; Li C; Yu R; Ma Z; Wang X; Zhao J; Liu X
Scand J Immunol; 2019 Jun; 89(6):e12761. PubMed ID: 30977163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
